October 21, 2016 7:09 PM ET


Company Overview of Alnylam Pharmaceuticals, Inc.

Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an investigational RNAi therapeutic that is in Phase I clinical trial for the treatment of hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-AS1 for the trea...

300 Third Street

3rd Floor

Cambridge, MA 02142

United States

Founded in 2002

369 Employees





Key Executives for Alnylam Pharmaceuticals, Inc.

Chief Executive Officer and Executive Director
Age: 53
Total Annual Compensation: $710.3K
Age: 53
Total Annual Compensation: $530.5K
Principal Financial Officer, Chief Business Officer and Senior Vice President
Age: 44
Total Annual Compensation: $441.1K
Chief Medical Officer and Executive Vice President of Research & Development
Age: 53
Total Annual Compensation: $500.1K
Principal Accounting Officer, Vice President of Finance and Treasurer
Age: 41
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2015.

Alnylam Pharmaceuticals, Inc. Key Developments

Alnylam Pharmaceuticals, Inc. Announces Data Monitoring Committee for the Phase 3 APOLLO Study of Patisiran in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy

Alnylam Pharmaceuticals, Inc. announced that the Data Monitoring Committee (DMC) for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) met on October 7, 2016 and recommended continuation of the trial without modification. The APOLLO DMC met at the request of the Company following the decision – announced on October 5, 2016 – to discontinue development of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). The DMC will continue to meet periodically per their remit to monitor the overall safety of patisiran in the APOLLO study through its completion. The APOLLO study has completed enrollment of 225 patients at 44 sites in 19 countries, between December 2013 and January 2016.

Alnylam Pharmaceuticals, Inc. - Special Call

To discuss ALN-HBV for the treatment of hepatitis B virus (HBV) infection

Alnylam Pharmaceuticals, Inc. - Special Call

To discuss the company's discontinues revusiran development

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alnylam Pharmaceuticals, Inc., please visit www.alnylam.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.